Parker Institute for Cancer Immunotherapy
American cancer research institute
From Wikipedia, the free encyclopedia
The Parker Institute for Cancer Immunotherapy (PICI) is an American program focused on the acceleration of cancer immunotherapy located in San Francisco. The institute includes over 40 laboratories from several key cancer centers, Weill Cornell, Stanford Medicine, Gladstone Institute, UCLA, University of Pennsylvania, and the Dana-Farber Cancer Institute.[1]
| Parent institution | Parker Foundation |
|---|---|
| Founder | Sean Parker |
| Established | April 13, 2016 |
| Mission | Accelerate the development of breakthrough immune therapies to turn all cancers into curable diseases. |
| Focus | Cancer immunotherapy |
| President | Karen E. Knudsen |
| Key people | Ira Mellman |
| Location | 1 Letterman Drive, Suite D3500 , , , United States |
| Website | www |
History
The institute was established in 2016 through the Parker Foundation by a $250 million grant from Sean Parker.[2] The institute was originally focused around three key areas of research, modification of T-cells, boosting the patient response to immunotherapy drugs, and research on novel targets. Jeffrey Bluestone was the inaugural president of the institute. [3]
Structure
PICI uses an organizational model to tie funding and science together. The PICI Network includes a number of cancer research centers. The PICI network involves: